Insmed (INSM) Misses Q3 EPS by 12c; Reports Cash and Cash Equivalents of $846.6M

Insmed (NASDAQ: INSM) reported Q3 EPS of ($0.96), $0.12 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $46.8 million versus the consensus estimate of $50.68 million.

For earnings history and earnings-related data on Insmed (INSM) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• FDA grants priority review to Insmed's Arikayce for MAC lung disease
• Evercore lifts Ciena rating on AI-driven optical networking boom